Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Carboplatin + Durvalumab + Etoposide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 6||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 98 PD-L1/PD-1 antibody 67||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, and in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer (FDA.gov).|
|Etoposide||Vepesid||EPEG|Eposin|VP-16|VP-16-213||TOPO2 inhibitor 4||Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung small cell carcinoma||not applicable||Carboplatin + Durvalumab + Etoposide||FDA approved||Actionable||In a Phase III (CASPIAN) trial that supported FDA approval, Imfinzi (durvalumab) in combination with Vepesid (etoposide) and Paraplatin (carboplatin) or Platinol (cisplatin) resulted in significantly improved overall survival (13.0 vs 10.3 mo, HR=0.73, p=0.0047) compared to platinum-etoposide therapy in patients with untreated extensive-stage small cell lung cancer (PMID: 31590988; NCT03043872).||31590988|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04745689||Phase II||AZD2811 + Durvalumab Cisplatin + Durvalumab + Etoposide Carboplatin + Durvalumab + Etoposide||Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)||Recruiting||USA||3|
|NCT04397003||Phase II||Carboplatin + Durvalumab + Etoposide Durvalumab + Tremelimumab Durvalumab + Personalized cancer vaccine + Tremelimumab||Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) and Tremelimumab in Extensive Stage Small Cell Lung Cancer||Not yet recruiting||USA||0|
|NCT03963414||Phase I||Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Etoposide||A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC||Recruiting||USA||0|